Clearmind Medicine Inc Ordinary Shares CMND
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy
-
Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment
-
SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
-
Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
-
Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment
-
Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment
-
Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders
-
Clearmind Medicine: New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss Drug
Trading Information
- Previous Close Price
- $1.24
- Day Range
- $1.22–1.24
- 52-Week Range
- $0.94–10.26
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $5.03 Mil
- Volume/Avg
- 25,685 / 1.6 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company’s intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 4
Valuation
|
Metric
|
CMND
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 7.75 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CMND
|
|---|---|
Quick Ratio | 1.68 |
Current Ratio | 1.71 |
Interest Coverage | — |
Quick Ratio
CMND
Profitability
|
Metric
|
CMND
|
|---|---|
Return on Assets (Normalized) | −57.56% |
Return on Equity (Normalized) | −547.21% |
Return on Invested Capital (Normalized) | −128.66% |
Return on Assets
CMND
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Vmnkcczdz | Nmckb | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Czsyblx | Pnrjxdl | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Fmyvnhsz | Kqjkbtb | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Qqtwzgsb | Ngyjrs | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Nblkbmht | Qnvgd | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Rmrnwtmh | Qzsjm | $28.1 Bil | |||
| Moderna Inc
MRNA
| Xkbzdwln | Shqmx | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Dvtypsfr | Ycg | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Bpljxmkw | Gqvssgs | $13.4 Bil | |||
| Incyte Corp
INCY
| Lsqxqbfy | Rxvspsp | $12.7 Bil |
United States